Therapy Areas: Autoimmune
Shed launches Low-Dose Naltrexone
5 March 2025 - Telehealth clinic Shed announced on Tuesday that it has introduced Low-Dose Naltrexone (LDN), a therapeutic solution for individuals managing chronic pain, autoimmune diseases and metab...
AbbVie receives positive CHMP opinion for upadacitinib in giant cell arteritis
28 February 2025 - Pharmaceutical company AbbVie (NYSE:ABBV) announced on Friday that it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for ...
OncoHost partners Gustave Roussy cancer institute to study predictive markers for immune-related adverse events
27 February 2025 - Israel-based technology company OncoHost announced on Wednesday that it has partnered with European cancer centre Gustave Roussy to identify non-invasive biomarkers for immune-relat...
Hemogenyx Pharmaceuticals administers first dose of HG-CT-1 in AML trial
24 February 2025 - Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has administered the first human dose of HG-CT-1, its proprietary CAR-T cell therapy, t...
Devonian files patent for Thykamine as antifibrotic agent
19 February 2025 - Pharmaceutical company Devonian Health Group Inc (TSXV: GSD) (OTCQB: DVHGF) announced on Wednesday that it has filed a new patent application for the use of Thykamine as an antifibr...
Johnson & Johnson reports publication of new nipocalimab data on potential to treat IgG-driven diseases
13 February 2025 - Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) on Thursday announced the publication of data in mAbs, a peer-reviewed, open access journal, detailing the uni...